Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
MA Wörns, A Weinmann, K Pfingst… - Journal of clinical …, 2009 - journals.lww.com
Methods Thirty-four patients with advanced HCC were treated with sorafenib regardless of
liver function and prior anticancer therapy. Adverse events (AEs) were graded using …
liver function and prior anticancer therapy. Adverse events (AEs) were graded using …
[引用][C] Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
MA WARNS, A WEINMANN, G OTTO… - Journal of clinical …, 2009 - pascal-francis.inist.fr
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in
Consideration of Concomitant Stage of Liver Cirrhosis CNRS Inist Pascal-Francis CNRS …
Consideration of Concomitant Stage of Liver Cirrhosis CNRS Inist Pascal-Francis CNRS …
[引用][C] Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
W MA - J Clin Gastroenterol, 2009 - cir.nii.ac.jp
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in
consideration of concomitant stage of liver cirrhosis | CiNii Research CiNii 国立情報学 …
consideration of concomitant stage of liver cirrhosis | CiNii Research CiNii 国立情報学 …
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
MA Wörns, A Weinmann, K Pfingst… - Journal of Clinical …, 2009 - europepmc.org
Methods Thirty-four patients with advanced HCC were treated with sorafenib regardless of
liver function and prior anticancer therapy. Adverse events (AEs) were graded using …
liver function and prior anticancer therapy. Adverse events (AEs) were graded using …
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concimitant stage of liver cirrhosis
MA Worns, A Weinmann, K Pfingst… - Journal of Clinical …, 2009 - eprints.gla.ac.uk
GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit
for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child …
for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child …
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
MA Wörns, A Weinmann, K Pfingst… - Journal of clinical …, 2009 - pubmed.ncbi.nlm.nih.gov
Goals and background The multikinase inhibitor sorafenib provides survival benefit for
patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh …
patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh …
[引用][C] Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
MA Wörns, A Weinmann, K Pfingst… - Journal of Clinical …, 2009 - cir.nii.ac.jp
Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in
Consideration of Concomitant Stage of Liver Cirrhosis | CiNii Research CiNii 国立情報学研究所 …
Consideration of Concomitant Stage of Liver Cirrhosis | CiNii Research CiNii 国立情報学研究所 …